Location Sciences Group Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Location Sciences Group Plc LSE:LSAI London Ordinary Share GB00BGT36S19 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.175 56,200 08:00:00
Bid Price Offer Price High Price Low Price Open Price
0.16 0.19 0.175 0.175 0.175
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Mgmt Invt Offices, Open-end 0.54 -1.38 - - 4.56
Last Trade Time Trade Type Trade Size Trade Price Currency
12:53:38 O 55,000 0.181 GBX

Location Sciences (LSAI) Latest News

Location Sciences (LSAI) Discussions and Chat

Location Sciences Forums and Chat

Date Time Title Posts
27/2/202322:48Location Sciences - mobile location intelligence852
15/2/202313:02LOCATION 🧭 LOCATION 🧭 LOCATION 🧭290
12/9/202008:58New Contract9

Add a New Thread

Location Sciences (LSAI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Location Sciences (LSAI) Top Chat Posts

Top Posts
Posted at 14/1/2022 13:51 by plunge
There is a lot of useful content and discussion on the Location Sciences #LSAI Telegram forum. You can always join it.
Posted at 01/1/2022 14:03 by tima441
Just re-reading some of the placing & other info:

On 25 May 2021 1,842,500,000 ordinary shares of 0.1p were issued at 0.2p pursuant to a placing, subscription and broker option .......... At the same time 42,500,000 ordinary shares were issued at the market value on day of admission of the shares at 0.66p to the non-executive directors in lieu of their first-year fees.

They must have been happy that 0.66p was a good price!
I suspect that the announcement of plans has taken longer than expected. But underlying position unchanged.

On the tax losses.... the note in the accounts says:
"Subject to the UK tax authority's agreement, the Group has UK tax losses of approximately £20,200,000 (2019: £19,680,000) available to carry forward and offset against future taxable profits arising from the same trade. The Group has a potential deferred tax asset of £3,840,000 (2019: £3,340,000) which will not be recognised until it is regarded as more likely than not that there will be sufficient taxable profits from which the tax losses can be deducted. In addition, no deferred tax asset is recognised in respect of future tax deductions on exercise of share options."

I'm not sure exactly what constitutes "same trade" or other relevant tax rules but feel pretty sure this is a major factor in the Concert Party plans

2022 should be interesting!

Posted at 30/12/2021 09:02 by pwhite73
tima441 - "So the number of shares that are in free float might be just 10%"

The number of shares that are in free float cannot be less than 25% and if any concerted party own more than 29.99% then they have to make a bid for the company unless the takeover rules are waived by the London Stock Exchange.

The share price is clearly moving in the right direction and there may be things afoot but AIM/small cap companies are notorious for ripping off small shareholders no matter how small their percentage holding. For all the buying the price is making little progress suggesting there are large sellers in the background or placing shares are being forward sold at a discount. Having said all that I can understand why this would still be worth a small punt.

Posted at 30/12/2021 09:00 by plunge
Here is another enlightening post from Muck165 on the LSE chat forum.

Always useful to look at time lines…

Hughes/Kamani invest in Avacta early 2020
They shortly then set upM19, and get exclusive B2C rights, and non exclusive B2B rights to the Avacta test.
M19 tried to get their own RSPT test away, but that seems to have failed, largely I think because it’s an antibody not an antigen test.
Then in April it seems Hughes and Kamani lumped more cash into M19 Healthcare (see charges registered at companies house)
In May they, with a concert group of family, Cheshire based investors, and notably Stephenson of M19, invest in LSAI, a business on its knees, ostensibly to drive the existing business. But shortly thereafter they give notice to the 2 remaining legacy Directors (promising to ensure they benefit from the EXISTING business), and begin to sell down assets.
From June/July onwards M19 is like tumbleweed on social media..weird for sales and marketing experts. We now know that in this period their focus has been getting HUA for AffiDx, building Saturn Pass, and potentially also Agile.
They trademarked Meduflow in November, but despite the HUA appear to have done next to nothing to promote it. Perhaps they don’t need to because of deals going on behind the scenes?
Whatever, I’m convinced that there was zero reason for the concert party to buy into LSAI unless it was M19 linked, and the fact LSAI has £20m of prior trading losses to use may well have been a primary driver.

Posted at 28/12/2021 21:44 by plunge
We may see further upticks in the share price if punters (especially from the Avacta board) see LSAI as a potential play in tying up with Medusa 19.
Posted at 28/12/2021 07:36 by tima441
What's the future hold? - not advice!

I think this is key....if my maths right...& lump Directors with Concert Party...
- They currently have around 757m shs out of 2.6bil. Just under 30%.
- If they exercise all warrants & options they will have around 2.7bil out of 4.6bil shs outstanding I.e. almost 60%. 
- 757m cost them approx £1.5m afaik
- Roughly another 2bil will cost them around £4m. (most 0.2p.. some higher. Say another £4m cash into co. But will not exercise yet - as they will not want to bid

What next?
stressing this is just my guess:
- Do a big placing at 1p (or more)... and buy @medusa19_
- Big placing at 1p... then trading at say 1.5p.... everyone happy!!!!!

Potential Placing
- Again stressing just a guess & idle musings:
Issue 10bil shs at 1p = £100m cash
Total shs out 12.6bil 
- Concert Party subscribe for 1.5bil new shs giving them 2.2bil in total (17.5%) but after exercise of options & warrants 4.2bil out of 12.6bil i.e. almost 30% (keeping under bid threshold)

- £100m from placing
- £4m from from warrants/options exercise

Buy Medusa19 
- Hughes & Kamani invested £20m in Dec 2020 & have built significant business including recently:
AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU.
- LSAI pay £50m(?) for Medusa19?
- Possibly add Saturn Pass too?

Other actions:
- Rename LSAI as Medusa19
- Integrate Verify with SaturnPass if synergies exist? Or
Divest previous business
- Consolidate shares 10:1 so 1.26bil outstanding  with say £50m cash 
- Possibly take stake(s) in one or more LFT manufacturer? (ABDX? ODX?) or better to remain ind from manufacturers?

Enterprise value?
1.26 bil shs trading at say 15p = £189m mkt cap

Concert Party
420m shs @ 15p = £63m
Vs cost 
270m @ 2p = £5.4m
150m @ 10p = £15m
Total £20.4m

Hughes/Kamani get £30m profit on original Medusa19 outlay. Not unreasonable seed finance uplift? 

I welcome feedback, comments or alternative views!

Posted at 22/12/2021 11:10 by plunge
Speculation on the other side suggesting a reverse takeover of Medusa 19 is in the offing.

As long as the share price continues with an upward move, I will be happy with whatever transpires.

Posted at 10/12/2021 15:46 by plunge
From the link below, it looks like GeoProve is offering the exact same solution for validating location data that LSAI has done in the past.


Now the question is, has it reinvented the wheel or has it acquired the technology from LSAI? My guess it's the latter but let us see.

Posted at 22/10/2021 09:25 by plunge
The share price hasn't moved at all since today's news release and the time of this posting. It looks like the market doesn't think much of this disposal.

Either that or this Company is so far off the radar for most investors, it just hasn't registered. So, no surprise there.

Posted at 31/1/2021 10:02 by sunshine today

Multiple today’s market cap by 10, and your market cap is only £46M.

Your target is an tiny, extra £2.5M onto today’s market cap.

LSAI 0.78P Mid

1/ Tiny market capitalisation, just £4.6M , of that , Net cash £1.2M.

2/ Analyst , two months ago , projected medium term, annual revenues of $50M .;cd=&ved=2ahUKEwiq_ePO_abuAhWiz4UKHYbXByAQwqsBMAJ6BAgFEA0&

3/ LSAI company presentations, 80% margins on verify software.
( Found on LSAI company, investor page.)

4/ Based on a reasonable growth PE of 20 , that would equate to LSAI having a Market capitalisation of over £500M. ( 100 times plus , current share price )

4/ £19M unused tax loss

5/ New report 2021, from LSAI client, (InMarket) , with annual $100 revenues ( 2nd from last paragraph)

We’re The First And Only Company To Offer Certified Location Audience Data: InMarket is the first
and only company in the industry to offer certified Location Audience data, third-party verified for data
accuracy and precision by the industry leader Location Sciences. Location Certified audiences build trust
and allow brands to buy with confidence, knowing an independent third-party review has assured the
precision and accuracy of the chosen audience.

2nd from last paragraph from the report.

5/ Finally: About Location Sciences Group PLC: (LSAI)

Location Sciences is the pre-eminent global location verification provider to the $160 billion digital advertising industry. Working in partnership with brands, media agencies and suppliers to reduce ad-wastage and improve the effectiveness of location-based advertising campaigns.

The digital advertising market-place remains unregulated and un-monitored, with an estimated $19 billion wasted on ad-fraud in 2018. Location Sciences has developed Verify, the world's first independent location verification product. Utilising sophisticated machine learning and pattern recognition technologies, Verify detects location ad-fraud and shines a light on location data inaccuracy with the aim of bringing back integrity, transparency and trust to the market place

Location Sciences share price data is direct from the London Stock Exchange
Your Recent History
Location S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230607 16:00:44